Skip to main content

United StatesBreaking News

Grafa

Merck gains FDA approval for Keytruda plus Trodelvy in first-line TNBC

Merck (NYSE:MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy (sacituzumab govitecan-hziy), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (CPS ≥10).

Read more
Grafa
Cryptocurrency

Fed policy tug-of-war reshapes Bitcoin store-of-value rivals

  • Grayscale linked Bitcoin’s long-term outlook to Federal Reserve interest-rate policy, arguing that lower rates could support demand for digital store-of-value assets. 
  • The theme connects several major crypto assets through monetary policy, institutional investment flows and growing adoption of exchange-traded products. 
  • Persistent inflation, regulatory uncertainty and the risk of higher-for-longer interest rates remain key challenges for the sector. 
Read more